AdaptNK –Cell Therapy for High-risk Myeloid Disease
Phase 2 other active
Quick answer
AdaptNK –Cell Therapy for High-risk Myeloid Disease for Relapsed and/or refractory AML or MDS is a Phase 2 program (other) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Relapsed and/or refractory AML or MDS
- Phase
- Phase 2
- Modality
- other
- Status
- active